![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases The biomarkers to watch when](https://ars.els-cdn.com/content/image/1-s2.0-S0001731023008505-fx1.jpg)
glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases The biomarkers to watch when
Description
Many individuals start with GLP-1 medications before considering bariatric surgery later if additional support is needed
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases The biomarkers to watch when](https://www.empirical.health/_astro/glp1-biomarker-panel.Cm_YU6O-.svg)
The primary endpoint is change in FTND score from baseline, assessed at weeks 1, 4, 8, 12, and 24
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases The biomarkers to watch when](https://i.ytimg.com/vi/b_QTw69lPFw/hq720.jpg?sqp=-oaymwEhCK4FEIIDSFryq4qpAxMIARUAAAAAGAElAADIQj0AgKJD&rs=AOn4CLDNekNubi9EQeozlPqzP-TJgII_dg)
doi: 10.1016/j.physbeh.2016.04.013
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases The biomarkers to watch when](https://www.diabetesincontrol.com/wp-content/uploads/2012/08/www.diabetesincontrol.com_images_Mastery_Series_2012_08_dcms98hs.jpg)
Ozempic was submitted to the FDA for the treatment of patients with T2DM and peripheral artery disease (PAD)
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases The biomarkers to watch when](https://assets.cureus.com/uploads/figure/file/1314190/article_river_58859fd0ab6a11efafceffcdd999c5f2-WhatsApp-Image-2024-11-25-at-9.20.11-AM.png)
Off-Label Use: A Growing Concern GLP-1s approved for T2D are frequently used off-label for weight loss, raising concerns among both employers and health plans
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases The biomarkers to watch when](https://d29gxntfxoh80u.cloudfront.net/content/images/500x1000/699c71121d844.png)
pmid:33161163 13
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases The biomarkers to watch when](https://m3.healio.com/~/media/slack-news/dermatology/misc/infographics/2025/08_august/derm0725snchez-feliciano_ig1.jpg)
